Why the study?
Does the use of long-tapered sirolimus-eluting stents improve procedural success and safety compared to conventional drug-eluting stents in patients undergoing CTO recanalization?
Does the use of long-tapered sirolimus-eluting stents improve procedural success and safety compared to conventional drug-eluting stents in patients undergoing CTO recanalization?
Long-tapered sirolimus-eluting stents are technically feasible and safe for the percutaneous treatment of chronic total occlusions, particularly for long lesions.
Supports initial feasibility of long tapered SES in complex CTO; leaves open safety and efficacy confirmation in prospective trials.
BACKGROUND: Coronary chronic total occlusions (CTO) usually coexist with diffusely diseased coronary segments proximal and/or distal to the CTO segment. During percutaneous treatment of CTO, multiple overlapping stents are often needed to treat these long lesions. OBJECTIVES: Aim of this study is to report the first use of long, tapered coronary sirolimus-eluting stents (SES) in this setting. METHODS AND RESULTS: This is a retrospective analysis of 100 consecutive patients undergoing CTO recanalization following the hybrid algorithm. Procedural success rate was 89% (11 failures). Among the successful cases, "conventional" drug-eluting stents(DES) were used in 40(44.9%) patients, while in 49(55%) patients long-tapered SES were attempted with a success rate of 98% (1 cross-over to regular stents). Total stent length in the long-tapered DES group was higher compared to the "conventional" stenting group (76 ± 28 mm vs 46 ± 22 mm, P < .001), with a similar total number of stent (1.6 ± 0.8 vs 1.9 ± 0.8). At quantitative coronary analysis, proximal and distal segment involvement was more extended in patients undergoing long-tapered stenting, with longer overall lesion length. No differences in periprocedural complications and clinical outcomes at a mean follow-up of 303 ± 179 days were observed. CONCLUSIONS: The use of long tapered coronary DES is technically feasible and safe for the percutaneous treatment of CTOs, especially for patients presenting with long lesions.
No takes yet. Share an insight, caveat, or question.
Zivelonghi et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: